1 active not recruiting, 1 not yet recruiting. 2 Phase 3, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 2 | Active not recruiting 1, Not yet recruiting 1 |
| Phase 2 | 1 | Not yet recruiting 1 |
Follow Sasanlimab: new trials by email Literature Review of Sasanlimab trials Research Report on Sasanlimab
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Immuno-pet IMaging ResPonses AdministeRed Immune CheckpoiNt InhibiTor Sasanlimab, non-ablative radiotherapy, [89Zr]Zr-crefmirlimab berdoxam - NSCLC | Phase 2 / Phase 3 | Not yet recruiting | Radboud University Medical Center | 20 | 2025-02-01 | 2024-11-29 |
| A Study of Sasanlimab in People With Non-muscle Invasive Bladder Cancer PF-06801591, Bacillus Calmette-Guerin - Non-muscle Invasive Bladder Cancer | Phase 3 | Active not recruiting | Pfizer | 1068 | 2019-12-30 | 2026-10-15 |
Non-Muscle Invasive Bladder Neoplasms (1) · Urinary Bladder Neoplasms (1)
Pfizer (1) · Radboud University Medical Center (1)
Germany (2) · Australia (1) · Belgium (1) · Canada (1) · China (1) · France (1) · Italy (1) · Japan (1) · Netherlands (1) · Poland (1) · Russia (1) · South Korea (1) · Spain (1) · United Kingdom (1) · United States (1)
PMID 38189180, PMID 40450141, PMID 42177753
2023 (1)